We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App




Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler

By LabMedica International staff writers
Posted on 03 Jan 2020
Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. More...
The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.

Nova develops and manufactures state-of-the-art, whole blood point-of-care and critical care analyzers, as well as the most advanced instruments for cell culture monitoring in the biotechnology market. Nova’s biosensor technology is incorporated in its products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers for the rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for a broad range of cell culture applications.

Nova’s FLEX2 combines its MicroSensor Card chemistry technology with optical measurements and freezing point osmometry to offer an automated and comprehensive cell culture analyzer that eliminates chemistry sensor maintenance, increases analyzer speed, and reduces sample volume. With the OLS, FLEX2 uses a small sample volume of 5.6 mL for the 16-test assay to allow frequent sampling for this detailed look at culture performance. Up to 24 samples per day for each of 10 bioreactors can be analyzed in as fast as six minutes, with proven comparability to manual sampling. The OLS provides automated sampling, analysis, and feedback control of 10 bioreactors in as fast as one hour for chemistry results, with only 20 minutes needed for setup. The ability of OLS and FLEX2 to provide unaided capture of key cell culture attributes across 10 bioreactors saves hours of scientists’ time versus manual sampling and analysis, and eliminates after-hours cell culture monitoring.

“We are excited to launch the next addition to the BioProfile FLEX2 platform with the On-Line Autosampler. FLEX2 OLS represents the latest in cell culture automation technology and further demonstrates Nova’s leadership and history of innovation,” said Matt McRae, sales product line manager at Nova.

Related Links:
Nova Biomedical


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.